Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | PKM | P14618 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 5/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | PIM1 | P11309 | 2/20 | 0.59 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.59 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847035 | 1.00 | PPARG (0.78) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL2260054 | 1.00 | PPARG (0.78) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL2774800 | 0.95 | PPARG (0.73) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL4204124 | 0.92 | PPARG (0.69) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL4204121 | 0.92 | PPARG (0.69) | PPARGKDM4EALDH1A1MAPTPKM | |
| Trifluoroacetic Acid SCHEMBL6608290 | 0.92 | PPARG (0.67) | PPARGKDM4EALDH1A1MAPTPKM | |
| Trifluoroacetic Acid SCHEMBL6608295 | 0.92 | PPARG (0.67) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL12520464 | 0.89 | PPARG (0.73) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL1850984 | 0.89 | PPARG (0.73) | PPARGKDM4EALDH1A1MAPTPKM | |
| SCHEMBL1850981 | 0.89 | PPARG (0.73) | PPARGKDM4EALDH1A1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011091033-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7678916-B2 | Process | CIPLA LIMITED (IN) | 2010-03-16 | — | — | US | disclosed |
| US-7678916-B2 | Process | CIPLA LIMITED (IN) | 2010-03-16 | — | — | US | disclosed |
| WO-2010013141-A2 | SUBSTANTIALLY PURE ROSIGLITAZONE HYDROGEN SULFATE | ACTAVIS GROUP PTC EHF (IS) | 2010-02-04 | — | — | WO | disclosed |
| US-7598387-B2 | Synthesis of antidiabetic rosiglitazone derivatives | CIPLA LIMITED (IN) | 2009-10-06 | — | — | US | disclosed |
| US-7598387-B2 | Synthesis of antidiabetic rosiglitazone derivatives | CIPLA LIMITED (IN) | 2009-10-06 | — | — | US | disclosed |
| EP-1756099-B1 | SYNTHESIS OF ANTIDIABETIC ROSIGLITAZONE DERIVATIVES | CIPLA LTD (IN) | 2008-11-12 | — | — | EP | disclosed |
| US-7351832-B2 | Process for the preparation of thiazolidinedione derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-04-01 | — | — | US | disclosed |
| US-20070191611-A1 | Synthesis of antidiabetic rosigltazone derivatives | CIPLA LIMITED (IN) | 2007-08-16 | — | — | US | disclosed |
| US-20070066662-A1 | PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES | SMITHKLINE BEECHAM PLC | 2007-03-22 | — | — | US | disclosed |
| US-7091359-B2 | Process for the preparation of thiazolidinedione derivatives | SMITHKLINE BEECHAM PLC (GB) | 2006-08-15 | — | — | US | disclosed |
| US-20060106221-A1 | Process for the preparation of thiazolidinedione derivatives | SMITHKLINE BEECHAM PLC | 2006-05-18 | — | — | US | disclosed |
| US-20030092742-A1 | Process for the preparation of thiazolidinedione derivatives | SMITHKLINE BEECHAM P.L.C. | 2003-05-15 | — | — | US | disclosed |
| EP-1028960-B1 | PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-04-23 | — | — | EP | disclosed |
| US-20020120150-A1 | Process for the preparation of thiazolidinedione derivatives | SMITHKLINE BEECHAM P.L.C. | 2002-08-29 | — | — | US | disclosed |
| EP-1219620-A1 | Process for the preparation of thiazolidinedione derivatives | SMITHKLINE BEECHAM PLC (GB) | 2002-07-03 | — | — | EP | disclosed |
| EP-1028960-A1 | PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES | SmithKline Beecham p.l.c. (GB) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999023095-A1 | PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066662-A1 | PROCESS FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES | ARSA, TALDO1, NAT1 | PPARG 441/4885KDM4E 4296/4885ALDH1A1 150/4885 |
| US-20030092742-A1 | Process for the preparation of thiazolidinedione derivatives | NAT1, CYP2F1, TALDO1 | PPARG 528/4885KDM4E 3929/4885ALDH1A1 180/4885 |
| US-20070191611-A1 | Synthesis of antidiabetic rosigltazone derivatives | PPARD, PPARG, GLP1R | PPARG 2/4885KDM4E 843/4885ALDH1A1 312/4885 |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | PPARG, PPARA, PPARD | PPARG 1/4885KDM4E 3515/4885ALDH1A1 2091/4885 |
| US-20020120150-A1 | Process for the preparation of thiazolidinedione derivatives | NAT1, TALDO1, CYP2F1 | PPARG 499/4885KDM4E 3992/4885ALDH1A1 182/4885 |
| US-20060106221-A1 | Process for the preparation of thiazolidinedione derivatives | ARSA, TALDO1, NAT1 | PPARG 441/4885KDM4E 4296/4885ALDH1A1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.